Key result
The authors question the necessity of corticosteroid therapy for amiodarone-induced pulmonary toxicity, suggesting the underlying process may be metabolic rather than immunologic.
Why the study?
Does corticosteroid therapy improve reversal of pulmonary injury compared to discontinuing amiodarone alone in patients with amiodarone pulmonary toxicity?
Does corticosteroid therapy improve reversal of pulmonary injury compared to discontinuing amiodarone alone in patients with amiodarone pulmonary toxicity?
Answers are grounded in this paper and cite their sources.
This letter questions whether corticosteroid therapy provides additional clinical benefit beyond simply discontinuing the drug for amiodarone-induced pulmonary toxicity.
Letters and Corrections1 June 1983Amiodarone and Pulmonary EffectsMICHAEL D. DAKE, M.D., JEFFREY A. GOLDEN, M.D.MICHAEL D. DAKE, M.D.Search for more papers by this author, JEFFREY A. GOLDEN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-6-1028_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with great interest the recent article by Marchlinski and associates on the pulmonary toxicity of amiodarone (1). Previously published experience suggests that pulmonary injury may resolve when drug treatment is stopped and treatment with corticosteroids is started (2-6). But on the basis of immunofluorescence and electron microscopic studies, Marchlinski and colleagues have questioned the need for corticosteroid therapy because pathologic data suggested a metabolic rather than an immunologic process. In addition, the clinical benefit of steroid therapy beyond that achieved by simply discontinuing the amiodarone remains unclear because all reported patients who had reversal of...References1. MARCHLINSKI F, GANSLER T, WAXMAN H, and JOSEPHSON M. Amiodarone pulmonary toxicity. Ann Intern Med. 1982;97:839-45. LinkGoogle Scholar2. SOBOL S and RAKITA L. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation. 1982;65:819-24. CrossrefMedlineGoogle Scholar3. ROTMENSCH H, LIRON M, TUPILSKI M, and LAMIADO S. Possible association of pneumonitis with amiodarone therapy [Letter]. Am Heart J. 1980;100:412-3. CrossrefMedlineGoogle Scholar4. HEGER J, PRYSTOWSKY E, and JACKMAN W. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981;305:539-45. CrossrefMedlineGoogle Scholar5. RILEY S, WILLIAMS S, and COOKE N. Alveolitis after treatment with amiodarone. Br Med J 1982;284:161-2. CrossrefMedlineGoogle Scholar6. HARRIS L, MCKENNA W, ROWLAND E, HOLT D, STOREY G, and KRIKLER D. Side effects of long-term amiodarone therapy. Circulation. 1983;67:45-51. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: MICHAEL D. DAKE, M.D.; JEFFREY A. GOLDEN, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA general overview of amiodarone toxicity: Its prevention, detection, and managementThe efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillationLysosomesAmiodarone lung: Pathologic finding in clinically toxic patientsPneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapyElectron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicityAmiodarone pneumonitis: three further cases with a review of published reports.Amiodarone Pulmonary ToxicityAmiodarone and PneumonitisMICHAEL DAN, M.D., JOEL GREIF, M.D. 1 June 1983Volume 98, Issue 6Page: 1028-1028KeywordsCorticosteroid therapyDrugsElectron microscopyImmunofluorescenceSteroid therapyToxicity ePublished: 1 December 2008 Issue Published: 1 June 1983 PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Dake et al. (1983) conducted a letter in Amiodarone pulmonary toxicity. Corticosteroid therapy vs. Discontinuing amiodarone alone was evaluated. The authors question the necessity of corticosteroid therapy for amiodarone-induced pulmonary toxicity, suggesting the underlying process may be metabolic rather than immunologic.
Synapse has enriched 10 related papers. Consider them for comparative context: